AnaptysBio Announces $100M Buyback Plan; Announces To Manage Financial Partnership For Jemperli With GSK And Imsidolimab With Vanda After Planned Spin-Off Of First Tracks Biotherapeutics

AnaptysBio, Inc. (Nasdaq: ANAB) has authorized a $100 million stock repurchase plan for its outstanding common stock. Following the planned spin-off of First Tracks Biotherapeutics on April 20, 2026, AnaptysBio will manage financial partnerships for its products Jemperli with GSK and imsidolimab with Vanda. The company aims to operate with limited full-time employees and minimal operating expenses, starting with approximately $140-$145 million in net cash and investments.